Evidence map›Paper›PMID 41136546›Full record

ArticleScientific reports2025

Serum tyrosine level is an independent factor for hepatocellular carcinoma development and mortality in patients with chronic liver disease.

Mikita Oi, Takao Miwa, Yuki Utakata, Masashi Aiba, Shinji Unome, Tatsunori Hanai, Makoto Shiraki, Naoki Katsumura, Yasuhiro Kawashima, Masahito Shimizu

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mikita OiDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Takao MiwaDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan. miwa.takao.a6@f.gifu-u.ac.jp.
Yuki UtakataDepartment of Internal Medicine, Chuno Kosei Hospital, 5-1 Wakakusadori, Seki, Gifu, 501-3802, Japan.
Masashi AibaDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Shinji UnomeDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Tatsunori HanaiDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.
Makoto ShirakiDepartment of Internal Medicine, Chuno Kosei Hospital, 5-1 Wakakusadori, Seki, Gifu, 501-3802, Japan.
Naoki KatsumuraDepartment of Internal Medicine, Chuno Kosei Hospital, 5-1 Wakakusadori, Seki, Gifu, 501-3802, Japan.
Yasuhiro KawashimaDepartment of Gastroenterology, Nagoya Central Hospital, 3-7-7 Taiko, Nakamura-ku, Nagoya, 453-0801, Aichi, Japan.
Masahito ShimizuDepartment of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.

Funding

Japan Society for the Promotion of Science 24K18908
6 · The paper itself

Abstract

The study aimed to investigate the independent effects of serum branched-chain and aromatic amino acid levels on hepatocellular carcinoma (HCC) development. This multicenter retrospective study included patients with chronic liver disease (CLD) from two institutions in Japan. Amino acid imbalance was assessed using BCAA and tyrosine levels. Factors associated with the development of HCC and mortality were assessed using Fine-Gray competing risk and Cox proportional hazards regression models, respectively. Among 563 patients, the median age was 67 years, and 51% were male. During a median follow-up period of 3.5 years, 14% (n = 80) of the patients developed HCC and 23% (n = 130) died. Given mortality as a competing risk, multivariable analysis showed that the serum tyrosine level (sub-distribution hazard ratio [HR], 1.01; 95% confidence interval [CI], 1.00-1.02) was an independent risk factor for the development of HCC. Similarly, using the development of HCC as a time-dependent covariate, the serum tyrosine level (HR, 1.01; 95% CI, 1.01-1.02) and development of HCC (HR 2.91; 95% CI 1.75-4.81) were independent risk factors for mortality. The serum tyrosine level is an independent risk factor for the development of HCC and mortality in patients with CLD.

Indexed as

Carcinoma, HepatocellularLiver DiseasesLiver NeoplasmsTyrosineAgedChronic DiseaseFemaleHumansJapanMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesRisk FactorsTyrosineAmino acid imbalanceBranched-chain amino acidsLiver cirrhosisMalnutritionSurvival

Identifiers

PMID41136546
PMCPMC12552657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.